Intio, Inc. Information
Contact top employees from
Intio, Inc.
Summary
Intio, Inc. is a private company that has been in the industry for 21 years. The company currently specializes in the Medical Devices area. The position of the President & CEO is occupied by Morgan Nields. Its headquarters is located at Broomfield, Colorado, USA. The number of employees ranges from 25 to 100. The annual revenue of Intio, Inc. varies between 5.0M and 25M. Total funding of the company - $8.1M. To connect with Intio, Inc. employee register on SignalHire.
Organization Website | intio.us |
Social Links |   |
Phone Number | 303-800-3700 |
Industries | |
Headquarters Location | 325 Interlocken Parkway, Broomfield, CO, 80021 US |
Employees Size | 10-50 employees |
Specialties | interventional oncology |
SIC Code | 5047 |
DMA Code | Denver Metropolitan Area |
Founded | 2005 |
Estimated Annual Revenue | $5.0M - 25M |
Operating Status | Independent Company |
Competitors
Founded | Type | Employees | Revenue | Funding | |
|---|---|---|---|---|---|
| 2006 | Privately Held | 1 - 25 | 5M | $55.6M | |
| 2004 | Privately Held | 25 - 100 | 8.4M | $209.2M | |
| 2001 | Privately Held | 100 - 250 | 20.4M | $148.1M | |
| 1979 | Public Company | 250 - 500 | 6.5M | $296.4M |
Employees Turnover 4 quarter 2025
Length of Employment
Employee tenure at Intio, Inc. shows a diverse range of experience levels:
7% for 5–7 years93% have over 11 years of service at Intio, Inc.Contact top employees from
Intio, Inc.
Morgan Nields
President & CEO
Paul Mardirosian
Software Test Engineer
Similar Companies
FAQ
Intio, Inc. operates in the Medtech industries. More details can be found on the official website: intio.us.
The headquarters of Intio, Inc. are located in Broomfield, United States.
The current CEO of Intio, Inc. is Morgan Nields
You can contact Intio, Inc. by phone at 303-800-3700.
Intio, Inc. currently employs 10-50 people.
Intio, Inc.'s revenue is approximately 7.8M.
Well-known competitors of Intio, Inc. include Bio2 Medical, Inc, Benvenue Medical, Spine Wave, Inc. and INOVIO Pharmaceuticals, Inc..
